Brenda Dennis
Primary Care · Glen Dale, WVNPI 1184933004
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 384 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$934
- Novo Nordisk$710
- AbbVie$651
- Bayer$314
- Boehringer Ingelheim$253
- plus $2K from 32 others
What the payments were for
- Food & beverage$6,208100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 61 | $1,083 |
| Lilly USA, LLC | 61 | $934 |
| Novo Nordisk | 46 | $710 |
| AbbVie | 42 | $651 |
| Bayer | 20 | $314 |
| Boehringer Ingelheim | 13 | $253 |
| Pfizer | 15 | $224 |
| Merck | 11 | $193 |
| E.r. Squibb & Sons, L.L.C. | 10 | $154 |
| Exact Sciences | 9 | $152 |
| GSK | 10 | $144 |
| Novartis | 9 | $138 |
| Mylan Specialty L.p. | 7 | $127 |
| Xeris Pharmaceuticals, Inc. | 6 | $102 |
| Sanofi-aventis U.S. LLC | 6 | $99 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $96 |
| Johnson & Johnson | 6 | $86 |
| Kowa Pharmaceuticals America, Inc. | 5 | $78 |
| Daiichi Sankyo Inc. | 5 | $78 |
| Amarin Pharma, Inc. | 5 | $64 |
| Boston Scientific | 2 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Avanir Pharmaceuticals, Inc. | 3 | $47 |
| Amgen | 3 | $46 |
| Supernus Pharmaceuticals, Inc. | 3 | $39 |
| Astellas Pharma US Inc | 2 | $34 |
| Verona Pharma, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Lundbeck LLC | 2 | $30 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Abbott | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Vertex | 1 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $11 |
How this compares
$6,208 in reported general payments places this provider in the 95th percentile of 43 primary care providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 159 | $106,041 |
| JardianceEmpagliflozin | 97 | $105,879 |
| JanuviaSitagliptin Phosphate | 51 | $46,033 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $44,943 |
| XareltoRivaroxaban | 60 | $43,776 |
| FarxigaDapagliflozin Propanediol | 36 | $41,776 |
| OzempicSemaglutide | 43 | $36,307 |
| TrulicityDulaglutide | 36 | $33,268 |
| Tresiba Flextouch U-200Insulin Degludec | 57 | $32,593 |
| LinzessLinaclotide | 39 | $25,628 |
| MyrbetriqMirabegron | 44 | $25,310 |
| MounjaroTirzepatide | 24 | $24,539 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $19,796 |
| ViberziEluxadoline | 13 | $19,422 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $13,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $224 | $106,041159 claims |
| Boehringer IngelheimJardiance | $253 | $105,87997 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $144 | $64,73898 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $934 | $57,80760 claims |
| MerckJanuvia | $193 | $46,03351 claims |
| AbbVieLinzess, Viberzi | $651 | $45,05052 claims |
| AstraZenecaFarxiga, Symbicort | $1,083 | $44,92449 claims |
| Johnson & JohnsonXarelto | $86 | $43,77660 claims |
| Novo NordiskOzempic | $710 | $36,30743 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $25,31044 claims |
| NovartisEntresto | $138 | $8,39913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $31 | $7,44916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 primary care providers in West Virginia.
Other primary care in Glen Dale
- Jessica FrankeGlen Dale$2K
- Amanda WakimWheeling$169K
- Brenda HashemBerkeley Springs$8K
- Molly WhiteCharleston$5K
- Richard SutherlandMartinsburg$4K
- Kayla MeadeHuntington$3K
- Crystal Clark-CrookshanksSummersville$3K
- Jerica BoboRomney$2K
- Alisa EllisonHinton$2K
- Amber BellMorgantown$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.